Boston Scientific Corporation

Quick facts

Marketed products

• Anticoagulation with heparin · Cardiovascular
  Heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.
• P2Y12 antagonist
• Varithena® · Cardiovascular / Vascular
  Varithena is a microfoam formulation of polidocanol that destroys varicose veins by causing endothelial damage and subsequent vein closure.

Phase 3 pipeline

• Anti-coagulation therapy
• Anti-platelet therapy · Cardiovascular
  Anti-platelet therapy inhibits platelet aggregation to prevent blood clots and reduce thrombotic events.
• polidocanol injectable foam, 0.125%
• polidocanol injectable foam, 0.5% · Dermatology
  Polidocanol works by causing endothelial damage and subsequent thrombosis in the targeted vein.
• polidocanol injectable foam, 1.0% · Cardiovascular
  Polidocanol works by causing endothelial damage and subsequent thrombosis in the treated vein, leading to fibrosis and closure.
• Thienopyridine · Other

Phase 2 pipeline

• BGC20-0582 · Oncology
  BGC20-0582 is a drug that targets the PD-1 receptor.
• Polidocanol Endovenous Microfoam 0.125%
• Tremelimumab immunotherapy

Phase 1 pipeline

• BTG-002814
• Market-approved OAC
• Non-Vitamin K Oral Anticoagulant

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Boston Scientific Corporation portfolio CI brief
• Boston Scientific Corporation pipeline updates RSS